Bright Minds Biosciences Inc. (DRUG) Balance Sheet

NASDAQ: DRUGAssets, liabilities, debt and equity over 7 years.

DRUG balance sheet, FY2025

September 30, 2025 · Canadian dollars

C$84.4M assets = C$2.4M liabilities + C$82.0M equity

What it ownsC$84.4MCash & ST investments: C$82.9M (98.2%)Cash & ST investmentsC$82.9M · 98%Receivables: C$413,071 (0.5%)Other current: C$987,911 (1.2%)PP&E: C$111,968 (0.1%)=How it is financedC$84.4MCurrent liabilities: C$2.3M (2.8%)Other LT liabilities: C$41,249 (0.0%)Shareholders’ equity: C$82.0M (97.2%)Shareholders’ equityC$82.0M · 97%

Both columns are drawn to the same scale: what DRUG owns equals what it owes plus shareholders’ equity. Hover a block for its value.

DRUG financial health

Debt / equity0.00
Low leverage · C$0.00 of debt for each $1 of equity
Equity / assets97.2%
Equity-funded · of assets funded by shareholders
Cash / debt65,917.1%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles0.0%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal FY2025.

DRUG balance sheet trends, FY2019–FY2025

MetricTrendThenLatestChange
Total assetsC$163,971FY2019C$84.4MFY2025+183.1%/yr
Total liabilitiesC$36,708FY2019C$2.4MFY2025+100.4%/yr
Shareholders’ equityC$127,262FY2019C$82.0MFY2025+193.9%/yr
Cash & short-term investmentsC$79,991FY2019C$82.9MFY2025+218.1%/yr
Total debtC$139,911FY2022C$125,777FY2025−3.5%/yr
Net cash (debt)C$11.5MFY2022C$82.8MFY2025+C$71.3M
Working capitalC$43,283FY2019C$82.0MFY2025+C$81.9M
Debt / equity0.01FY20220.00FY2025−0.01
Shares outstanding1.3MFY20196.9MFY2025+32.3%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

DRUG assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

DRUG liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

DRUG debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

DRUG balance sheet in Canadian dollars

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Assets
Cash & short-term investmentsC$82.9MC$5.7MC$6.7MC$11.6MC$19.8MC$799,929C$79,991
Cash & equivalentsC$82.9MC$5.7MC$6.7MC$11.6MC$19.8MC$799,929C$79,991
Short-term investmentsC$61,927—C$86,250C$86,250C$86,250——
ReceivablesC$413,071C$50,224C$36,981C$155,779C$110,146C$0C$0
InventoryC$0C$0−C$36,981C$0C$0C$0C$0
Other current assetsC$987,911C$216,628C$64,673C$164,429C$168,207C$78,287C$0
Total current assetsC$84.3MC$6.0MC$6.8MC$11.9MC$20.0MC$878,216C$79,991
Property, plant & equipment (net)C$111,968C$117,658C$66,413C$138,863C$0C$0C$0
Goodwill & intangible assetsC$0C$0C$0C$0C$2,000C$2,000C$2,000
Long-term investmentsC$0C$0C$0C$0C$0C$0C$0
Other non-current assetsC$0C$0C$0C$0C$0C$0C$81,980
Total assetsC$84.4MC$6.1MC$6.9MC$12.1MC$20.0MC$880,216C$163,971
Liabilities
Accounts payableC$1.7MC$407,548C$182,307C$1.2MC$596,573C$138,423C$36,708
Short-term debtC$84,528C$79,384C$73,549C$67,928———
Total current liabilitiesC$2.3MC$528,683C$280,856C$1.5MC$638,573C$150,923C$36,708
Long-term debtC$0C$0C$0C$0C$0C$0C$0
Lease obligationsC$125,777C$118,960C$73,549C$139,911C$0——
Other long-term liabilitiesC$41,249C$39,576C$0C$71,983C$596,573C$138,423C$0
Total liabilitiesC$2.4MC$568,259C$280,856C$1.5MC$638,573C$150,923C$36,708
Shareholders' equity
Common stock & paid-in capitalC$123.2MC$35.4MC$33.9MC$32.2MC$27.1MC$980,661C$205,980
Retained earnings (deficit)−C$46.6M−C$34.3M−C$31.5M−C$24.2M−C$9.2M−C$559,094−C$78,717
Accumulated other comprehensive incomeC$5.4MC$4.0MC$3.4MC$2.5MC$1.6MC$161,300−C$81,980
Total shareholders' equityC$82.0MC$5.5MC$6.6MC$10.5MC$19.4MC$729,293C$127,262
Key figures
Total debtC$125,777C$118,960C$73,549C$139,911———
Net cash (debt)C$82.8MC$5.6MC$6.7MC$11.5M———
Working capitalC$82.0MC$5.5MC$6.5MC$10.5MC$19.4MC$727,293C$43,283
Tangible book valueC$82.0MC$5.5MC$6.6MC$10.5MC$19.4MC$727,293C$125,262
Shares outstanding6.9M4.3M3.7M2.5M1.8M1.3M1.3M
Current ratio36.1011.3224.268.1131.385.822.18
Quick ratio35.6810.9124.168.0031.125.302.18
Debt / equity0.000.020.010.01———
Equity / assets97.2%90.7%95.9%87.2%96.8%82.9%77.6%

Quarterly columns are labeled by the month the quarter ended. Figures in Canadian dollars as reported (latest annual report filed December 23, 2025); data from EODHD.

DRUG financial position

At the end of fiscal 2025 (September 30, 2025), Bright Minds Biosciences had total assets of C$84.4 million (up 1,282.9% from a year earlier), total liabilities of C$2.4 million and shareholders' equity of C$82.0 million. It held C$82.9 million in cash and short-term investments against C$0.1 million of debt, a net cash position of C$82.8 million. Its current ratio was 36.10. In the latest quarter (ended June 30, 2026) total assets were C$310.8 million and equity C$308.3 million.

Related: DRUG income statement, DRUG cash flow statement, DRUG key metrics. See the DRUG stock overview for the latest quote and news.

DRUG balance sheet FAQ

What are Bright Minds Biosciences's total assets?

Bright Minds Biosciences reported total assets of C$84.4 million at the end of fiscal 2025 (September 30, 2025), compared with C$6.1 million a year earlier.

How much debt does Bright Minds Biosciences have?

Bright Minds Biosciences had C$0.1 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.00.

How much cash does Bright Minds Biosciences have?

Bright Minds Biosciences held C$82.9 million in cash and short-term investments at the end of fiscal 2025; with C$0.1 million of debt that is net cash of C$82.8 million.

What is Bright Minds Biosciences's book value?

Bright Minds Biosciences's shareholders' equity (book value) was C$82.0 million at the end of fiscal 2025.

What is Bright Minds Biosciences's current ratio?

Bright Minds Biosciences had current assets of C$84.3 million and current liabilities of C$2.3 million, a current ratio of 36.10 (it can cover its short-term obligations).

Biotechnology: balance sheet